Indoline Serotonergic Agents for Non-Hallucinogenic 5-HT2A Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new non-hallucinogenic 5-HT2A agonist molecules to treat mental illnesses and neurological diseases, as existing psychedelics have hallucinogenic side effects that limit their use outside clinical settings, and non-hallucinogenic 5-HT2A agonist therapeutic development is in its infancy.
Innovation Solution
Development of indoline compounds that modulate serotonin receptor subtypes, particularly 5-HT2A, through direct binding, offering a non-hallucinogenic approach for treating mental illnesses and neurological diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classic psychedelics (mescaline, DMT, psilocybin, LSD) are used to treat neuropsychiatric diseases, then therapeutic effectiveness is improved through 5-HT2A receptor activation, but hallucinogenic side effects worsen and impede use outside clinical settings
Solution Approach 1:
The patent modifies molecular parameters of classic psychedelics by replacing the tryptamine or phenethylamine core structure with an indoline scaffold and adjusting substituent patterns (R1, R2, R3, R4, R5, R6 groups) to tune receptor interaction. This chemical parameter change maintains 5-HT2A agonist activity while eliminating hallucinogenic effects, as evidenced by compounds showing therapeutic potential without producing hallucinations in preclinical models.
Solution Approach 2:
The patent introduces specific local modifications at different positions of the indoline core structure. For example, R1 at the nitrogen position can be H, C1-6alkyl, or aryl groups, while R2-R6 on the aromatic ring can be independently selected from H, halo, C1-6alkyl, C1-6alkoxy, or other substituents. These localized structural changes allow precise control over receptor binding properties to achieve non-hallucinogenic activity while preserving therapeutic benefits.
2Object-affected harmful factors
If non-hallucinogenic 5-HT2A agonist analogs are developed, then hallucinogenic side effects are reduced, but therapeutic development remains in its infancy and effectiveness needs improvement
Solution Approach 1:
The indoline compounds of the patent are designed to universally activate 5-HT2A receptors while maintaining non-hallucinogenic properties across different substitution patterns. The core indoline structure with appropriate substituent groups (R1-R6) provides a universal scaffold that achieves both goals: eliminating hallucinogenic effects while maintaining therapeutic effectiveness for neuropsychiatric conditions through consistent 5-HT2A agonist activity.
Solution Approach 2:
The patent creates composite molecular structures by combining the indoline core with various functional groups and substituent patterns. This composite approach allows optimization of pharmacological properties - the indoline nucleus provides the basic 5-HT2A binding capability while different R group combinations (alkyl, aryl, heterocyclic substituents) fine-tune the activity profile to achieve non-hallucinogenic therapeutic agents with improved effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The indoline compounds provide a therapeutic option for treating psychosis, mental illnesses, and neurological diseases without hallucinogenic effects, leveraging direct serotonin receptor modulation.
Implementation Method 1
Compounds of the present application modulate the activity of serotonin receptor subtypes, in particular 5-HT2A, by direct binding to these receptors.
Data Source
AI summary
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptors in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses and CNS disorders and/or associated endophenotypes and/or symptom clusters. Wherein Q is (Q3).